17 Class Action Settlements You Can Claim in November 2026

Seventeen class action settlements are open for claims in November 2026, including Visa/Mastercard ($167.5M), CVS, and GoodRx ($32M). Five require no proof. Deadlines range from Nov 2 to Dec 29, 2026. Some settlements, like Everbridge ($85M), require broker records.

Original reporting
Published Nov 1, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$V
Neutral
medium confidence
Mentioned
$V · $MA · $CVS · $GDRX
Relevance
4/10
AlphAI data visualization · based on openclassactions.com
Decision brief

The 30-second read

$VNeutralLow
01

Why it matters

While the settlements involve notable U.S. companies, the financial impact per company is limited and primarily reputational.

02

Market read

The settlements provide modest short‑term sentiment cues but no actionable trading opportunities.

03

What to watch

The settlements may set precedents for future privacy and fee litigation, affecting industry peers not directly named.

Relevance 4/10Novelty 5/10Timing: claim window opens November 2026

Background

The article lists 17 class‑action settlements open for claims in November 2026, detailing payout amounts and claim requirements.

Company-level read

Ticker impact

$VNeutralMedium confidence
Context

Visa is a party to the $167.5M nonbank ATM fee settlement disclosed in the article.

Expected impact

likely slight pressure as market prices in the settlement cost.

Evidence & confidence

Settlement cost is a one‑time expense; investors may view it as a minor hit.

$MANeutralMedium confidence
Context

Mastercard is also a party to the $167.5M nonbank ATM fee settlement disclosed in the article.

Expected impact

likely slight pressure as market prices in the settlement cost.

Evidence & confidence

One‑time settlement expense with limited long‑term effect.

$CVSNeutralHigh confidence
Context

CVS is named in the CVS website and app privacy settlement (up to $5‑$10 per claimant).

Expected impact

minimal impact; price likely unchanged.

Evidence & confidence

Settlement amount per claimant is tiny relative to CVS's market cap.

$GDRXNeutralHigh confidence
Context

GoodRx is a party to the $32M privacy settlement disclosed in the article.

Expected impact

minimal impact; price likely unchanged.

Evidence & confidence

Settlement size is small relative to GoodRx's market value.

Market effects

Highlights ongoing consumer privacy and fee‑related litigation across financial and health‑care sectors.

U.S. consumers may see modest refunds; no broader regional effect.

Limited to U.S. listed firms involved in the settlements.

Counterpoint

Investors could view the settlements as a catalyst for tighter regulatory scrutiny, potentially increasing future compliance costs.

Key entities

  • Visa

    U.S. payments network involved in ATM fee settlement.

  • Mastercard

    U.S. payments network involved in ATM fee settlement.

  • CVS Health

    Health‑care retailer facing privacy settlement.

  • GoodRx

    Prescription‑price comparison platform facing privacy settlement.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$CVSHigh

CVS Health Falls as Medicare Advantage Scrutiny Adds to Breakup Overhang

CVS Health (CVS) fell 3.5% due to Medicare Advantage regulatory risks and uncertainty around its planned business separation. CMS proposed tighter oversight, raising concerns about Aetna's compliance costs. CVS announced a split into two public companies, with risks tied to timing, approvals, and costs. Insider and hedge fund activity, along with analyst ratings, were also noted.

$NVDAMed

Wall Street's crowded AI trade is getting squeezed: Citi warns of $45.9 billion in vulnerable S&P bets, Griffin cuts major holdings and Druckenmiller heads for the sidelines

Citi reports 95% of S&P 500 futures long positions, totaling $45.9B, are underwater. Ken Griffin's Citadel reduced stakes in SpaceX, Amazon, AMD, and Apple, while adding to others. Stanley Druckenmiller remains cautious. JPMorgan forecasts leveraged-loan defaults to rise. Nvidia faces SEC scrutiny over disclosures and chip exports.